Skip to main content

Advancing Precision Oncology Through Artificial Intelligence

By Waqas Haque, MD, MPH

In this latest edition of The Way Ahead: The Convergence of Technology and Cancer Care, Dr. Waqas Haque shares his perspectives on machine learning models for classifying cancer immunophenotypes in lung cancer; Insilico Medicine's artificial intelligence–driven process behind the development of INS018_055, a promising drug for idiopathic pulmonary fibrosis; the approval of lisocabtagene maraleucel for chronic lymphocytic leukemia/small lymphocytic lymphoma; and more! 

Continue reading

Multiple Myeloma Awareness Month 2024: What Patients Need to Know

For Multiple Myeloma Awareness Month this March, Oncology Data Advisor hosted a live panel discussion geared towards patients living with multiple myeloma. Dr. Rahul Banerjee, Dr. Alankrita Taneja, Dr. Richa Thakur, and Dr. Gurbakhash Kaur helped put the myriad of new developments in multiple myeloma treatment into perspective for patients and answered questions from the audience regarding current and future treatment strategies for multiple myeloma.  

Continue reading

Discovering Research Advances in Mesothelioma With Samuel Kareff, MD, MPH, and Estela Rodriguez, MD, MPH

In this Fellows Forum interview, Dr. Samuel Kareff speaks with Dr. Estela Rodriguez, Clinical Research Lead of the Thoracic Site Disease Group at the University of Miami Sylvester Comprehensive Cancer Center, about recent research advances in mesothelioma, the emerging roles of immunotherapy and biomarker testing, and the importance of ensuring access to care for patients with this rare disease.  

Continue reading

Emerging Technologies in Therapeutics and Diagnostics

By Waqas Haque, MD, MPH

In this latest edition of The Way Ahead: The Convergence of Technology and Cancer Care, Dr. Waqas Haque shares his perspectives on the approval of lifileucel, the first individualized tumor-infiltrating lymphocyte therapy, for advanced melanoma; updates on the EV-302 trial of enfortumab vedotin, an antibody-drug conjugate technology; a new blood test for colorectal cancer screening from Guardant Health; the Model Facts label to guide decisions using machine learning; and more!  

Continue reading

Rare Disease Day 2024: A Live Panel Discussion With Dr. Rahul Banerjee, Matthew Hadfield, Joseph Kalis, and Nagashree Seetharamu

Oncology Data Advisor® · Rare Disease Day 2024 With Rahul Banerjee, Matthew Hadfield, Joseph Kalis, and Nagashree Seetharamu On Rare Disease Day on February 29, members of the Oncology Data Advisor Editorial Board and Fellows Forum hosted a live panel discussion focused on the rare diseases that they treat, including tireless efforts underway to develop novel treatment strategies, enhance quality of life, and improve outcomes for patients.   Oncology Data Advisor: Hi, everyone, a...

Continue reading

Discovering Research Advances in Mesothelioma With Samuel Kareff, MD, MPH, and Estela Rodriguez, MD, MPH

In this Fellows Forum interview, Dr. Samuel Kareff speaks with Dr. Estela Rodriguez, Clinical Research Lead of the Thoracic Site Disease Group at the University of Miami Sylvester Comprehensive Cancer Center, about recent research advances in mesothelioma, the emerging roles of immunotherapy and biomarker testing, and the importance of ensuring access to care for patients with this rare disease.  

Continue reading

Expanding Access to Clinical Trials Through Decentralized Methods and Technology With Waqas Haque, MD, MPH, and Shaalan Beg, MD

In this installment of Oncology Data Advisor's Exploring AI in Oncology series, Dr. Waqas Haque speaks with Dr. Shaalan Beg, an Adjunct Associate Professor at the University of Texas (UT) Southwestern, who is spearheading efforts to decentralize clinical trials in oncology and expand access for eligible patients. Dr. Beg describes the tools that are currently in development for decentralizing trials, including the use of artificial intelligence (AI), natural language processing, and telehealth. Additionally, he shares his perspectives on transitioning to a career in industry.  

Continue reading

Oncology Data Advisor® Receives 2023 APEX® Award of Excellence for Health/Medical Websites

Oncology Data Advisor® is honored to receive an Award of Excellence in the Health/Medical Website category of the 2023 APEX® Awards for Publication Excellence. Awarded annually, the APEX Awards recognize excellence in publishing by professional communicators. Recognition is presented to outstanding publications that showcase imaginative strategies, in addition to creative and effective communication. Judging is based on distinction in graphic design, editorial content, and the ability to achieve...

Continue reading

National Cancer Prevention Month: Rising Trends and How to Combat Them With Samuel Kareff, Matthew Hadfield, Waqas Haque, and Joseph Kalis

In honor of National Cancer Prevention Month 2024, members of the Oncology Data Advisor Editorial Board and Fellows Forum sat down for a panel discussion about the rising incidence of cancer diagnoses, factors contributing to them, and how to counsel patients in light of these emerging trends.  

Continue reading

Breaking Developments in Neuroendocrine Tumor Research With Samuel Kareff, MD, MPH, and Aman Chauhan, MD

In this Fellows Forum interview, Samuel Kareff, MD, MPH, interviews Aman Chauhan, MD, Leader of the Neuroendocrine Tumor Program at the University of Miami, Sylvester Comprehensive Cancer Center, about how he became involved in neuroendocrine cancer research, the latest developments in novel therapies, and the future of using radiopharmaceuticals and theranostics to revolutionize the treatment of neuroendocrine tumors.  

Continue reading

Breaking Developments in Neuroendocrine Tumor Research With Samuel Kareff, MD, MPH, and Aman Chauhan, MD

In this Fellows Forum interview, Samuel Kareff, MD, MPH, interviews Aman Chauhan, MD, Leader of the Neuroendocrine Tumor Program at the University of Miami, Sylvester Comprehensive Cancer Center, about how he became involved in neuroendocrine cancer research, the latest developments in novel therapies, and the future of using radiopharmaceuticals and theranostics to revolutionize the treatment of neuroendocrine tumors.  

Continue reading

Updates on AI and Deep Learning for Cancer Detection and Outcomes Prediction

By Waqas Haque, MD, MPH

In this latest edition of The Way Ahead: The Convergence of Technology and Cancer Care, Dr. Waqas Haque shares his perspectives on a deep learning model for gallbladder cancer detection, a precision medicine platform for pancreatic ductal adenocarcinoma outcome prediction, and more!  

Continue reading

World Cancer Day 2024 With Oncology Data Advisor

In honor of World Cancer Day on February 4, members of the Oncology Data Advisor Fellows Forum and Editorial Board joined forces for a thought-provoking discussion about improving cancer care on a global scale, including treatment access, molecular testing, clinical trial diversity, and patient advocacy worldwide.  

Continue reading

Streamlining the Pathology Workflow Through Artificial Intelligence With Waqas Haque, MD, MPH, and Leif Honda of TriMetis

This second episode of Oncology Data Advisor's podcast series, Exploring Artificial Intelligence in Oncology, features Leif Honda, Chief Innovation Officer at TriMetis, a digital pathology company focused on improving patient outcomes by accelerating human tissue-based research, development, and testing. Dr. Waqas Haque, member of the Oncology Data Advisor Fellows Forum, speaks with Mr. Honda about the TriMetis Computer-Assisted Pathology (TCAP) AI platform, including how it was developed and trained, its capabilities for streamlining the pathology workflow, and the ongoing process of preparing it for clinical utility.  

Continue reading

Predicting Immune-Related Adverse Events Through Machine Learning With OncoHost: Dr. Waqas Haque, Dr. Matthew Hadfield, and Dr. Ofer Sharon

In this first episode of Oncology Data Advisor's new podcast series, "Exploring Artificial Intelligence in Cancer Care," Dr. Waqas Haque and Dr. Matthew Hadfield of the OncData Fellows Forum engage in a discussion with Dr. Ofer Sharon, CEO of OncoHost. Dr. Sharon provides an overview of the clinical need for increased knowledge of patients' probabilities of developing immune-related adverse events and explains the PROphet® platform, OncoHost's novel plasma-based, proteomic pattern analysis tool that uses a single blood sample to guide immunotherapy treatment decisions.  

Continue reading

Navigating the Residency and Fellowship Experience by Creating Opportunities in Oncology With Waqas Haque, MD

Oncology Data Advisor® · Navigating the Fellowship Experience by Creating Opportunities in Oncology With Waqas Haque In this Oncology Data Advisor® Fellows Forum interview, member Waqas Haque, MD, an Internal Medicine Resident at New York University, shares his medical training journey, the research he has conducted as Clinical Investigator Track Resident, his plans for applying to an oncology fellowship, advice for navigating the experience, tips for acquiring oncology exposure durin...

Continue reading

Insights from the State of AI Precision Oncology Conference

By Waqas Haque, MD, MPH In a virtual seminar held on December 12 of last year, the State of AI Precision Oncology brought together a group of scientists and oncologists to delve into the transformative impact of artificial intelligence (AI) in oncology. Dr. Doug Flora, the Executive Medical Director of Oncology Services at St. Elizabeth Healthcare and Chief Editor of the new journal, AI in Precision Oncology, curated discussions on early cancer detection, drug discovery, and data management. The...

Continue reading

A 2024 Kickoff Message From Dr. Rahul Banerjee, Editor in Chief

Many of us are ushering in the New Year singing "Auld Lang Syne" (or some version of those lyrics) with an eye toward ensuring that old acquaintances never be forgotten. Conversely, as we ring in 2024, it's worth noting how many of our old-acquaintance oncology drugs have actually remained at our side. Pembrolizumab was first approved in September 2014 for metastatic melanoma, while blinatumomab was first approved in December 2014 for B-cell acute lymphoblastic leukemia (ALL). (Feel old yet?) No...

Continue reading

The Way Ahead: The Convergence of Technology and Cancer Care: December 2023 Edition

By Waqas Haque, MD, MPH

In this new post of the Oncology Data Advisor Fellows Forum blog series, "Convergence of Technology and Cancer Care," Waqas Haque, MD, MPH, delves into the latest technological advancements seeking to improve the care and outcomes of patients with cancer. In this edition, Dr. Haque explores the potential of an artificial intelligence–based program for providing treatment recommendations, the FDA's groundbreaking approval of the first cell-based gene therapy for sickle cell disease, and integrating a diagonal approach for improving access to cancer treatments and technologies globally. 

Continue reading

Exploring Epcoritamab for Relapsed/Refractory Follicular Lymphoma With Dr. Matthew Hadfield, Dr. Alankrita Taneja, Dr. Tahi Ahmadi, and Dr. Jacqueline Nielsen

Recently, Genmab and AbbVie announced updated results of the phase 1/2 EPCORE™ NHL-1 clinical trial of epcoritamab (epco) for patients with relapsed/refractory follicular lymphoma. In this interview, Dr. Matthew Hadfield and Dr. Alankrita Taneja of the Oncology Data Advisor Fellows Forum speak with Dr. Tahi Ahmadi, Chief Medical Officer at Genmab, and Dr. Jacqueline Nielsen, Therapeutic Area Head for Hematology at AbbVie, about the significance of these results, the benefits of epcoritamab's subcutaneous administration, management of adverse events, and the future role of epcoritamab in the treatment landscape for follicular lymphoma.  

Continue reading